{"id":727565,"date":"2023-02-01T07:08:45","date_gmt":"2023-02-01T12:08:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/"},"modified":"2023-02-01T07:08:45","modified_gmt":"2023-02-01T12:08:45","slug":"zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/","title":{"rendered":"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK and SAN DIEGO, Feb.  01, 2023  (GLOBE NEWSWIRE) &#8212; Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences.<\/p>\n<p>\n        <strong>Presentation Details:<\/strong>\n      <\/p>\n<p>\n        <strong>Event:<\/strong>\u00a0Guggenheim Healthcare Talks | Oncology Day<br \/><strong>Date\/Time:<\/strong>\u00a0Wednesday, February 8th, 2023 at 9:00 a.m. ET<br \/><strong>Location:<\/strong>\u00a0New York City<\/p>\n<p>\n        <strong>Event:<\/strong>\u00a0SVB Securities Global Biopharma Conference<br \/><strong>Date\/Time:<\/strong>\u00a0Tuesday, February 14th, 2023 at 3:00 p.m. ET<br \/><strong>Location:<\/strong>\u00a0Virtual<\/p>\n<p>Webcasts will be accessible through the Investors section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WeAbfx9p_t2SnmnQH8hdRkeMGpq12-fYeslpqKhI8VED-qwwUrzi10RQ3wPxAeOHcjHQtv-l_72nGxZSaSW5Mg==\" rel=\"nofollow noopener\" target=\"_blank\">www.zentalis.com<\/a>. Following the events, archived webcasts will be available on the Zentalis website.<\/p>\n<p>\n        <strong>About Zentalis Pharmaceuticals<\/strong><br \/>\n        <br \/>Zentalis\u2122 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Utilizing its Integrated Discovery Engine, the Company is developing a focused pipeline of potentially best-in-class oncology candidates, which include azenosertib (ZN-c3), a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in both New York and San Diego.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WeAbfx9p_t2SnmnQH8hdRjOhbA2ZvQK8d5u1fVCctf7G-DziCLXyhQgirebbVPJHRxFMCqEcmt_quZXBAp97v9YZAf8_pRJuT3jfSqN-X0rqUXg-1hpsFWsMTmkBOn5n2Lr3jCOnjUEll6ml1DUrZKuV_aKxRs5yPOebsUCjkHWJJBhznBZjM9Y00pXQIG8H57UKnuOntamNJ2qX7Nzcss8H46DZdW3u0UjG_pZo4vU=\" rel=\"nofollow noopener\" target=\"_blank\">www.zentalis.com<\/a>. Follow Zentalis on Twitter at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XIhF_7jxTokclbWnuOZzyVZiDGLERjmiKYsKYLGf42KP-ldm1Aeypxu0YrmHViCuv9IyW83DpjdQn_vaDEnMDT_wQtrcGIHIlZSApfSVOmxLEKA_ArFffWOkHCKFFPdhR4UL-1WEdmkRNp-_PcMGuxBVQnpv9KOmG3p4fqAX8l7kWaw-PWYEC5RAR3hsCuU2epf8awL76_OhZ5GSNktYOMiHPBb1Wd0nh8KN9veUdfk=\" rel=\"nofollow noopener\" target=\"_blank\">@ZentalisP<\/a>\u00a0and on LinkedIn at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FGuoX6eGlnOrbBh-XXRD2xaM_uO5gGLbSR48EabR_H7xTWDfmzv3HjKGU6YbN0f_R0PZMbdSKXv8pPPBOJkxKdjUoKbjIsxgRimzukin_gG_O7mKMZpxkFiXY_GTTnb726UKYRWRYUa08VByi_H5WBpS2s2B5FzdPP4_q9JGaBnDRhR1n4XXFwHgYcJmpsDtMoqnRtCeV_DD_P0uwoxURQ8W3sQK1DH8D6w3PiMYJjBIWQajO1apL7MisbzwhPhQDfyH-qN0RUOYTOxSrkcYPOJOfxCe8SE0eu6cQTtbhNy-xp5R8NeJybS5Yd64vx9MdCK15jgG5rGoGAv8-GBFe0o3fW2u3Qr5eWn_5esvSTWGGOHfr1LgCaovkSZWpT7A\" rel=\"nofollow noopener\" target=\"_blank\">www.linkedin.com\/company\/zentalis-pharmaceuticals<\/a>.<\/p>\n<p>\n        <strong>Investor Contacts:<\/strong>\n      <\/p>\n<p>Adam D. Levy, PhD, MBA<br \/>Senior Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JCTegVE2zoVniFgRHBC3zaMEO3ytWs0Yl-Pspx7jlAfrzUOXfXCXG2EM8IP9We43EW_NdtxcoJAp5ueB-MS7FTsaPH_1cMWmE8NLt_ju_IE=\" rel=\"nofollow noopener\" target=\"_blank\">alevy@zentalis.com<\/a><\/p>\n<p>Alexandra Roy<br \/>Solebury Strategic Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G6f0X-zSS1bhmSDQ9BNxKi5SKxio0W8apIa5TVyNF49h-PHHbPs7tc-l9CRsvy_R3SK-fwo7aYtENcn3SsgNHqfUwVhJ67_7vamCWHjmnwk=\" rel=\"nofollow noopener\" target=\"_blank\">aroy@soleburystrat.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>Julia Deutsch<br \/>Solebury Strategic Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aosoz8Bl72sb3kODq0OkeQ2-_2N35sBFzUFVP2fgD27GukfGBxFED78GwL5TFSTI61EIZxpVaZ219xKE-PneZSRUGEika_2diBx_XHH6-5qvSMx3yw22ILwzqYYxlJbs\" rel=\"nofollow noopener\" target=\"_blank\">jdeutsch@soleburystrat.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NGU0ZTg4N2EtYWNmMi00NjZmLThhZWYtYTI0MWNiMGRjNTU3LTEyMDYyOTY=\/tiny\/ZENTALIS-PHARMACEUTICALS.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences. Presentation Details: Event:\u00a0Guggenheim Healthcare Talks | Oncology DayDate\/Time:\u00a0Wednesday, February 8th, 2023 at 9:00 a.m. ETLocation:\u00a0New York City Event:\u00a0SVB Securities Global Biopharma ConferenceDate\/Time:\u00a0Tuesday, February 14th, 2023 at 3:00 p.m. ETLocation:\u00a0Virtual Webcasts will be accessible through the Investors section of the Company\u2019s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website. About Zentalis Pharmaceuticals Zentalis\u2122 Pharmaceuticals, Inc. is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-727565","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences. Presentation Details: Event:\u00a0Guggenheim Healthcare Talks | Oncology DayDate\/Time:\u00a0Wednesday, February 8th, 2023 at 9:00 a.m. ETLocation:\u00a0New York City Event:\u00a0SVB Securities Global Biopharma ConferenceDate\/Time:\u00a0Tuesday, February 14th, 2023 at 3:00 p.m. ETLocation:\u00a0Virtual Webcasts will be accessible through the Investors section of the Company\u2019s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website. About Zentalis Pharmaceuticals Zentalis\u2122 Pharmaceuticals, Inc. is a &hellip; Continue reading &quot;Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T12:08:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences\",\"datePublished\":\"2023-02-01T12:08:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/\"},\"wordCount\":291,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/\",\"name\":\"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=\",\"datePublished\":\"2023-02-01T12:08:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/","og_locale":"en_US","og_type":"article","og_title":"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences - Market Newsdesk","og_description":"NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences. Presentation Details: Event:\u00a0Guggenheim Healthcare Talks | Oncology DayDate\/Time:\u00a0Wednesday, February 8th, 2023 at 9:00 a.m. ETLocation:\u00a0New York City Event:\u00a0SVB Securities Global Biopharma ConferenceDate\/Time:\u00a0Tuesday, February 14th, 2023 at 3:00 p.m. ETLocation:\u00a0Virtual Webcasts will be accessible through the Investors section of the Company\u2019s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website. About Zentalis Pharmaceuticals Zentalis\u2122 Pharmaceuticals, Inc. is a &hellip; Continue reading \"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-01T12:08:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences","datePublished":"2023-02-01T12:08:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/"},"wordCount":291,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/","name":"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=","datePublished":"2023-02-01T12:08:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDA3MSM1MzgzODg1IzIxOTQ3NDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zentalis-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=727565"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727565\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=727565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=727565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=727565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}